Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
Open accessThe DOI matches its Crossref record; 236 of the 237 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
The protein p53, known as the “Guardian of the Genome”, plays an important role in maintaining DNA integrity, providing protection against cancer-promoting mutations. Dysfunction of p53 is observed in almost every cancer, with 50% of cases bearing loss-of-function mutations/deletions in the TP53 gene. In the remaining 50% of cases the overexpression of HDM2 (mouse double minute 2, human homolog) protein, which is a natural inhibitor of p53, is the most common way of keeping p53 inactive. Disruption of HDM2-p53 interaction with the use of HDM2 antagonists leads to the release of p53 and expression of its target genes, engaged in the induction of cell cycle arrest, DNA repair, senescence, and apoptosis. The induction of apoptosis, however, is restricted to only a handful of p53wt cells, and, generally, cancer cells treated with HDM2 antagonists are not efficiently eliminated. For this reason, HDM2 antagonists were tested in combinations with multiple other therapeutics in a search for synergy that would enhance the cancer eradication. This manuscript aims at reviewing the recent progress in developing strategies of combined cancer treatment with the use of HDM2 antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“According to these three clear binding sites, a variety of structural types of MDM2 inhibitors have been reported, among which nine have entered clinical trials (RG7112, RG7388/RO6839921, MK-8242, AMG232, SAR405838, DS-3032b, HDM201, NVP-CGM097 and APG-115) (Fig. 3), with a variety of scaffold types [15–18].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, MDM2 inhibitors sensitize cells to a range of other therapies, including radiation, thus enhancing response to standard-of-care therapy for GBM (6).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MDM2 inhibitors can enhance response to both radiation therapy (RT) and temozolomide,7-9 the standard of care for GBM.”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–237 of 237
Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
Goethem, A. V., Yigit, N., Moreno‐Smith, M., Vasudevan, S. A., Barbieri, E., Speleman, F., Shohet, J. M., Vandesompele, J., & Maerken, T. V. (2017) · Oncotarget · doi:10.18632/oncotarget.18982 · Cited by 36
Chen, L., Pastorino, F., Berry, P., Bonner, J. J., Kirk, C., Wood, K. M., Thomas, H. D., Zhao, Y., Daga, A., Veal, G. J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32058 · Cited by 35 · cited 3×
“TMZ was evaluated in combination with RG7775 (idasanutlin prodrug) to treat neuroblastoma [55].”
BackgroundInfluentialZaman, S., Yu, X., Bencivenga, A. F., Blanden, A. R., Liu, Y., Withers, T., Na, B., Blayney, A. J., Gilleran, J., Boothman, D. A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1080 · Cited by 35 · cited 2×
“The results of this combination therapy on immunodeficient mice bearing TOV112D xenograft tumors have shown a significant synergistic effect on the tumor growth inhibition in comparison to the single treatment [103].”
BackgroundResultNutlin‐3 enhances sorafenib efficacy in renal cell carcinoma
Vatsyayan, R., Singhal, J., Nagaprashantha, L. D., Awasthi, S., & Singhal, S. S. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20875 · Cited by 34 · cited 4×
“This treat ent resulted in increased apoptosis hat was attribu o the increas d levels of proapoptotic PUMA protein when the soraf nib and nutlin-3 cotreatment was applied [75].”
BackgroundMethodInfluentialGu, D., Wang, S., Kuiatse, I., Wang, H., He, J., Dai, Y., Jones, R. J., Bjorklund, C. C., Yang, J., Grant, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103015 · Cited by 34
Zheng, M., Yang, J., Xu, X., Sebolt, J. T., Wang, S., & Sun, Y. (2010) · PubMed · Cited by 33
Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition
Prabakaran, P. J., Javaid, A. M., Swick, A. D., Werner, L. R., Nickel, K. P., Sampene, E., Hu, R., Ong, I. M., Bruce, J. Y., Hartig, G. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0969 · Cited by 32 · cited 2×
“Combination of radiation with AMG-232 was also evaluated in adenoid cystic carcinoma, resulting in tumor growth inhibition and total regression that remained for months after the treatment [50].”
BackgroundCarrillo, A. M., Hicks, M., Khabele, D., & Eischen, C. M. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0089 · Cited by 31
Conradt, L., Henrich, A., Wirth, M., Reichert, M., Lesina, M., Algül, H., Schmid, R. M., Krämer, O. H., Saur, D., & Schneider, G. (2013) · International Journal of Cancer · doi:10.1002/ijc.27916 · Cited by 30 · cited 4×
“Furthermore, a combination of the topoisomerase II inhibitor, etoposide, with nutlin-3a led to enhanced activation of effector caspases [46].”
BackgroundMethodInfluentialIn Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
Wei, S. J., Joseph, T., Sim, A. Y. L., Yurlova, L., Zolghadr, K., Lane, D., Verma, C., & Ghadessy, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062564 · Cited by 28
Antibody-Based Immunotherapy of Solid Cancers: Progress and Possibilities
Nicodemus, C. F. (2015) · Immunotherapy · doi:10.2217/imt.15.57 · Cited by 28 · cited 1×
“mAbs are the most successful therapeutic agents, for both, the solid tumors [200], and leukemias or lymphomas [201].”
BackgroundPhelps, D., Bondra, K., Seum, S., Chronowski, C., Leasure, J., Kurmasheva, R. T., Middleton, S., Wang, D., Mo, X., & Houghton, P. J. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25465 · Cited by 27 · cited 3×
“Midostaurin, was shown to synergize with CGM097 in AML cell models along with apoptosis induction [51,73].”
BackgroundMethodMetal Chaperones: A Holistic Approach to the Treatment of Alzheimer’s Disease
Adlard, P. A., & Bush, A. I. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00015 · Cited by 26
Voltan, R., Rimondi, E., Melloni, E., Rigolin, G. M., Casciano, F., Arcidiacono, M. V., Celeghini, C., Cuneo, A., Zauli, G., & Secchiero, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12139 · Cited by 26 · cited 3×
“ibrutinib nutlin-3 CLL CLL xenograft mouse models [72]”
BackgroundMethodInfluentialReuther, C., Heinzle, V., Nölting, S., Herterich, S., Hahner, S., Halilovic, E., Jeay, S., Wuerthner, J. U., Aristizabal Prada, E. T., Spöttl, G., et al. (2018) · Neuroendocrinology · doi:10.1159/000453369 · Cited by 25 · cited 21×
“Pr o- Su rv iv al Si gn al in g Pa th w ay s Ta rg et in g R as /R af /M EK /M A PK In hi bi to rs pimasertib SAR405838 - - different tumor types, Phase 1 NCT01985191[81] trametinib AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels AML, Phase 1b melanoma, Phase 1 [78,79] NCT02016729 NCT…”
BackgroundMethodInfluentialEvaluation of Zinc (II) chelators for inhibiting p53-mediated apoptosis
Morita, A., Ariyasu, S., Ohya, S., Takahashi, I., Wang, B., Tanaka, K., Uchida, T., Okazaki, H., Hanaya, K., Enomoto, A., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1535 · Cited by 25 · cited 1×
“Metal chelators have the ability to remove zinc from p53, what in turn leads to ‘mutant-like’ p53 form which cannot specifically bind to DNA [220].”
BackgroundHerting, F., Herter, S., Friess, T., Muth, G., Bacac, M., Šulcová, J., Umaña, P., Dangl, M., & Klein, C. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12756 · Cited by 25
RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas
Obrador-Hevia, A., Martinez-Font, E., Felipe-Abrio, I., Calabuig-Fariñas, S., Serra-Sitjar, M., López-Guerrero, J. A., Ramos, R., Alemany, R., & Martín-Broto, J. (2015) · Cancer Investigation · doi:10.3109/07357907.2015.1064534 · Cited by 24 · cited 2×
“trabectedin RG7112 fibrosarcoma and liposarcoma [56]”
BackgroundDrummond, C. J., Esfandiari, A., Liu, J., Lü, X., Hutton, C., Jackson, J., Bennaceur, K., Xu, Q., Makimanejavali, A. R., Bello, F. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10073 · Cited by 24
MDM2 antagonist nutlin‐3a sensitizes tumors to V‐ATPase inhibition
Schneider, L. S., Ulrich, M. P., Lehr, T., Menche, D., Müller, R., & von Schwarzenberg, K. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.04.005 · Cited by 20 · cited 3×
“Schneider and colleagues have reported that the archazolid/nutlin-3 combination results in synergistically induced cell death in p53wt-harboring cancer cells in vitro and in a glioblastoma xenograft model [105].”
BackgroundInfluentialChen, H., Xue, L., Huang, H., Wang, H., Zhang, X., Zhu, W., Wang, Z., Wang, Z., & Wu, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.042 · Cited by 20 · cited 3×
“In addition, in vivo experiment with human xenograft model of schwannoma has revealed that the small-molecules work together to impose apoptosis [98].”
BackgroundInfluentialOwen, C., & Stewart, D. A. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715586528 · Cited by 19 · cited 1×
“Pre-clinical data suggests that obinutuzumab is more efficient than rituximab in depleting B cells [205] and has a better toxicological profile, while rituximab therapy causes increased resistance generation [206,207].”
BackgroundSynergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
Urso, L., Cavallari, I., Silic‐Benussi, M., Biasini, L., Zago, G., Calabrese, F., Conte, P., Ciminale, V., & Pasello, G. (2017) · Oncotarget · doi:10.18632/oncotarget.17790 · Cited by 19 · cited 2×
“Urso and colleagues have investigated the synergy between nutlin-3 and rhTRAIL in malignant pleural mesothelioma (MPM) cell lines and RG7112 and rhTRAIL in the in vivo MPM mouse model [68].”
BackgroundWang, X., Zhang, S., Bao, J., & Liu, F. (2017) · Tumor Biology · doi:10.1177/1010428317701638 · Cited by 19 · cited 2×
“D ow re gu la to rs oridonin nutlin-3 osteosarcoma [63]”
BackgroundShimazu, K., Tada, Y., Morinaga, T., Shingyoji, M., Sekine, I., Shimada, H., Hiroshima, K., Namiki, T., Tatsumi, K., & Tagawa, M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3300-y · Cited by 18 · cited 2×
“O th er s metformin nutlin-3a malignant mesothelioma [107]”
BackgroundMEK'ing the Most of p53 Reactivation Therapy in Melanoma
Lee, J. T., & Herlyn, M. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.362 · Cited by 17 · cited 1×
“For example, MEK inhibition seems to result in transcriptional and posttranscriptional downregulation of the HDM2 gene, which in turn leads to lower HDM2 protein levels and increased activity of p53 [186].”
BackgroundGuo, Y. C., Li, Y., Wang, F., Xiang, B., Huang, X., Ma, H., & Gong, Y. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.10.008 · Cited by 13
Moschos, S. J., Sandhu, S. K., Lewis, K. D., Sullivan, R. J., Johnson, D. B., Zhang, Y., Rasmussen, E., Henary, H. A., & Long, G. V. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2575 · Cited by 12 · cited 6×
“Pr o- Su rv iv al Si gn al in g Pa th w ay s Ta rg et in g R as /R af /M EK /M A PK In hi bi to rs pimasertib SAR405838 - - different tumor types, Phase 1 NCT01985191[81] trametinib AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels AML, Phase 1b melanoma, Phase 1 [78,79] NCT02016729 NCT…”
BackgroundInfluentialCatizone, A. N., Good, C. R., Alexander, K. A., Berger, S. L., & Sammons, M. A. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1593643 · Cited by 12 · cited 1×
“Such a forced p53 release results in the expression of a plethora of p53-regulated genes, presenting a transcriptome landscape similar, but not identical to that of genotoxic p53 activation [3].”
BackgroundPerifosine plus nutlin‐3 combination shows a synergistic anti‐leukaemic activity
Voltan, R., Celeghini, C., Melloni, E., Secchiero, P., & Zauli, G. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08018.x · Cited by 11 · cited 2×
“The combination has been tested on six different leukemia cell lines and resulted in greater apoptosis and p53 protein expression induction in p53wt cell lines [86].”
BackgroundAn open invitation to the cancer immunology community.
Srivastava, P. K., Cerundolo, V., Knuth, A. K., & Allison, J. P. (2012) · Europe PMC (PubMed Central) · Cited by 11
Kay, B. P., Hsu, C., Lü, J., Sun, Y., Bai, S., Xin, Y., & D’Argenio, D. Z. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9269-x · Cited by 10 · cited 1×
“rhTRAIL induces selective apoptosis in cancer cells and leaves the normal cells unharmed [170,171].”
BackgroundPirich, T., Zwickl-Traxler, E., Pecherstorfer, M., & Singer, J. (2018) · Oncotarget · doi:10.18632/oncotarget.25714 · Cited by 9 · cited 1×
“Pre-clinical data suggests that obinutuzumab is more efficient than rituximab in depleting B cells [205] and has a better toxicological profile, while rituximab therapy causes increased resistance generation [206,207].”
BackgroundThe Proteasome as a Target for Cancer Treatment
Papandreou, C. N. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504060-00003 · Cited by 6 · cited 8×
“Tyrosi e kinase rec pt s are responsible for initiation, transmission, and regulatio of m ny cellular pathways connected to cell proliferati n and survival, such as JAK/STAT, PI3K/Akt/mTOR, and Ras/Raf/MEK/MAPK [177,178].”
BackgroundInfluentialPre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy
Pishas, K. I., Neuhaus, S. J., Clayer, M., Adwal, A., Brown, M. P., Evdokiou, A., Callen, D. F., & Neilsen, P. M. (2013) · Oncology Reports · doi:10.3892/or.2013.2454 · Cited by 5 · cited 2×
“The scientists have postulated that the key factor that contributes to the synergistic effects between these molecules is upregulation of DR5 receptor expression following the p53 activation [94].”
BackgroundWang, H. Q., Zubrowski, M. J., Emerson, E. O., Pradhan, E., Jeay, S., Wiesmann, M., Caponigro, G., Wuerthner, J., Schlegel, R., Cao, Z. A., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-5466 · Cited by 3 · cited 3×
“The proposed rationale for this synergism was the induction of a complementary set of anti-proliferative and apoptosis stimulating molecules by the combination of the compounds, since CGM097 induces p21 and Bax expression, while NVP-LGX818 causes the induction of p27 and Bim [80].”
BackgroundBorthakur, G. M., Duvvuri, S. R., Samudio, I. J., Kojima, K., Konopleva, M. Y., & Andreeff, M. (2009) · Blood · doi:10.1182/blood.v114.22.1738.1738 · Cited by 1 · cited 2×
“It has been used in combined therapy with idasanutlin, resulting in synergy in apoptosis induction in AML cell lines regardless of their p53 status [99].”
BackgroundMethod
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
Targeting apoptotic pathways for cancer therapy
Tian, X., Srinivasan, P. R., Tajiknia, V., Uruchurtu, A. S. S., Seyhan, A. A., Carneiro, B. A., Cruz, A. D. L., Pinho-Schwermann, M. P., George, A., Zhao, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179570 · Cited by 172
“The first approach uses agents targeting p53-negative regulators to activate WT p53, such as MDM2 inhibitors (69, 70).”
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
Skalniak, L., Kocik, J., Polak, J., Skalniak, A., Rak, M., Wolnicka-Glubisz, A., & Holak, T. (2018) · Cancers · doi:10.3390/cancers10110396 · Cited by 73
Self-citationMDM2: current research status and prospects of tumor treatment
Yao, Y., Zhang, Q., Li, Z., & Zhang, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03356-8 · Cited by 82
“Safe dose intravenous injection of RO6839921 showed good anti-tumor activity in osteosarcoma and AML xenograft models [87].”
Background
Metadata
- Authors
- Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L.
- Affiliations
- Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30–387 Krakow, Poland
- Jagiellonian University (PL)
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-07-19
- Volume
- 11
- Issue
- 7
- Pages
- 1014
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6678622
- OpenAlex
- W2963228228
- Cited by
- 46
- References
- 237
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 11 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 8
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Narodowe Centrum Nauki (UMO-2016/21/D/NZ7/00596)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, MDM2, combination therapy, anticancer activity, apoptosis, TP53 mutation, synergistic effect, cancer therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.